Citations

Mayo Clinic

Clear

88160 citation(s) found for "NA".

Surgically Diagnosed Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia in Asymptomatic Patients
Chen, Le , Matsuura, Yosuke , Yang, Ruxue, Fickel, Abigail, Ning, Guangyao, Sun, C J , Fickel, Abigail

Surgical Case Reports | June 30, 2026 | Volume: 12 | Issue: 1 | Pages: n/a

10.70352/scrj.cr.26-0123 | PMID 42404090 Get It

Health conditions and RSV-related Pediatric Intensive Care Unit admissions in children during their second RSV season
Zambrano, Laura, Newhams, Margaret M., Payne, Amanda B., Orzel-Lockwood, Amber O., Halasa, Natasha B., Calixte, Jemima, Chiotos, Kathleen, Crandall, Hillary , Cameron, Melissa A. , Coates, Bria M. , Michelson, Kelly N., Schuster, Jennifer E., Nofziger, Ryan A. , Chauhan, Jigar C., Maamari, Mia , Kong, Michele, Martine, Lora M., Guzman‐Cottrill, Judith A. , Bhumbra, Samina S. , Irby, Katherine , Staat, Mary Allen, Bradford, Tamara T. , Wellnitz, Kari, Ml, Stockwell, Zinter, Matt, Hymes, Saul, Levy, Emily R. , Biggs, Austin , Lindsey, Katherine, Campbell, Angela P., Simeone, Regina M. , Zambrano, Laura D. , Newhams, Margaret M. , Payne, Amanda B. , Halasa, Natasha , Calixte, Jemima M., Maddux, Aline B. , Chiotos, Kathleen , Kamidani, Satoshi , Zerr, Danielle M. , Gertz, Shira J. , Michelson, Kelly Nicole , Schuster, Jennifer E. , Chauhan, Jigar , Shein, Steven L. , Kong, Michele , Hume, Janet R. , Staat, Mary Allen , Wellnitz, Kari , Zinter, Matt S. , Schwartz, Stephanie P. , Hymes, Saul, Lindsey, Katherine N. , Campbell, Angela P. , Randolph, Adrienne G.

No container title available | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.26.26356705 Get It

Abstract Importance Respiratory syncytial virus (RSV) hospitalization rates are highest among children <2 years of age. RSV immunization with infant monoclonal antibody or maternal vaccine is recommended to protect all U.S. infants in their first RSV season. For certain high-risk children aged 8−19 months entering their second RSV season, the monoclonal antibody nirsevimab is recommended. Little is known regarding preexisting health conditions as risk factors for RSV-associated respiratory failure in children during their second season. Objectives To describe children admitted to the pediatric intensive care unit (PICU) for RSV during their second RSV season by preexisting health conditions, and to compare demographic and clinical characteristics across groups. Design, Setting, and Participants Surveillance registry of children 8-<24 months old admitted to the PICU in 30 pediatric hospitals in the 2023-2024/2024-2025 RSV seasons. All children had an RSV-positive respiratory sample and received respiratory support with high flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation (IMV). Exposure Preexisting health conditions potentially increasing risk of severe RSV disease. Main Outcomes and Measures Patients were classified into four mutually exclusive groups by preexisting health conditions: 1) U.S. nirsevimab eligible criteria, 2) other identified RSV risk conditions (with some evidence of increased risk for severe RSV), 3) other preexisting conditions, and 4) no preexisting conditions. Patient demographic characteristics and level of respiratory support received were compared. Results Among 574 children: 47 (8.2%) had U.S. nirsevimab eligibility criteria, 76 (13.2%) had other RSV risk conditions, 96 (16.7%) had other preexisting conditions, and 355 (61.8%) had none. A higher proportion of children with nirsevimab eligibility factors (40.4%) than those with other identified RSV risk conditions (17.1%) required IMV, which was higher than other (10.4%) or no (5.9%) preexisting health conditions (p trend <0.001). Conclusions and Relevance Approximately 20% of children admitted to the PICU with severe RSV were in the defined groups that met U.S. nirsevimab-eligibility criteria or that had an identified RSV risk condition associated with known risk for severe RSV. A considerable proportion of both groups of children required IMV for respiratory support. These findings may help inform future deliberations regarding U.S. second season nirsevimab-eligibility recommendations. Key Points Question What preexisting health conditions are present in children aged 8–<24 months admitted to the pediatric intensive care unit for severe RSV disease in their second RSV season and how do clinical outcomes differ? Findings Among 574 children, 8% were eligible for nirsevimab in the U.S. and 13% had other preexisting conditions with known risk for severe RSV. Children with preexisting conditions, particularly those eligible for nirsevimab, were more likely to require invasive mechanical ventilation than those without. Meaning These findings may inform future deliberations regarding which children in their second RSV season might benefit from RSV preventive products.
Targeting the S100A2–RAGE Pathway Restores AT2 Cell Identity and Mitigates Lung Fibrosis
Zhou, Changli , Bagherpoor, Alireza Jian, Deng, Wei, Tschumperlin, Daniel, Tan, Qi, Wellmerling, Jack H, Wellmerling, Jack , Tschumperlin, Daniel J. , Tan, Qi

American Journal of Respiratory Cell and Molecular Biology | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrcmb/aanag133 | PMID 42576310 Get It

Abstract Lung fibrosis, including idiopathic pulmonary fibrosis (IPF), represents a spectrum of progressive interstitial lung diseases characterized by disrupted epithelial repair, fibroblast activation, and excess extracellular matrix accumulation. A central feature of fibrotic progression is the loss of alveolar type 2 epithelial (AT2) cell identity and the emergence of aberrant transitional states that fail to support normal regeneration. Based on our re-analysis of multiple publicly available scRNA-seq datasets from the IPF Cell Atlas, S100A2 expression is tightly associated with basal-like reprogramming of AT2 cells and is a top upregulated gene at both mRNA and protein levels in IPF lungs. Furthermore, scRNA-seq data from human lung organoid models reveal that AT2 cells co-cultured with fibroblasts acquire a basal-like phenotype and express high levels of S100A2. Functionally, overexpression of S100A2 in human iPSC-derived lung alveolar epithelial type 2 (iAT2) cells leads to loss of AT2 cellular identity, increased generation of reactive oxygen species, and activation of RAGE signaling pathway. We demonstrate that pharmacologic inhibition of RAGE using Azeliragon preserves AT2 cell populations, associated with reduced oxidative stress in iAT2 cells, and significantly attenuates collagen deposition in bleomycin-induced lung fibrosis models. Collectively, our results indicate that S100A2 is a key driver of epithelial dysfunction in lung fibrosis, promoting loss of AT2 identity, aberrant basal fate acquisition, and persistent epithelial injury. Targeting the unrecognized S100A2–RAGE pathway may offer a new therapeutic strategy to restore epithelial homeostasis in lung fibrosis.
Defending the Ethical Permissibility of Laryngeal Transplantation
Lott, David G. , Ellertson, Marka , Grandjean, Danielle N. , Sj, Zacharias, Strome, Marshall, Beck, Annika T., Teven, Chad M., Zacharias, Stephanie R, Sharp, Richard R , Ellertson, Marka F. , Lott, David G , Zacharias, Stephanie R., Teven, Chad M. , Sharp, Richard R.

The American Journal of Bioethics | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1080/15265161.2026.2691944 | PMID 42377982 Get It

Differential survival with adjuvant immunotherapy in stage III acral versus non‐acral melanoma
Tran, Hue Thi Thu , Tran, Thuy Minh, Le, Duc Van, Shrestha, Raslina, Guo, Ruifeng Ray, Otley, Clark C. , Behl, Deepti , Nguyen, Giang Huong , Nguyen, Giang H , Tran, Hue T.T. , Shrestha, Raslina , Guo, Ray, Markovic, Svetomir N.

Journal of the European Academy of Dermatology and Venereology | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70567 | PMID 42378040 Get It

Beyond Photons: Emerging Advances and Clinical Potential of Proton Beam Therapy in Gynecological Malignancies
Chen, Le , Wang, Li , Bakshi, Hamid A. , Wang, Li

Radiation | June 30, 2026 | Volume: 6 | Issue: 3 | Pages: 23

10.3390/radiation6030023 Get It

Radiation therapy is central to the management of gynecological cancers, including endometrial, cervical, ovarian, and vaginal malignancies. Despite advances in photon-based techniques, treatment-related toxicity remains significant owing to the anatomical proximity of pelvic targets to critical organs at risk (OARs), including the bowel, bladder, and bone marrow. Proton beam therapy exploits the Bragg peak to deliver a precise dose at depth with minimal exit dose, potentially reducing OAR exposure. This review develops the physical principles, dosimetric evidence, and early clinical data for proton therapy in gynecological malignancies, including cervical, endometrial, ovarian, vaginal, and vulvar cancers. Major focus is given to clinical conditions where conventional brachytherapy is not practical, and proton therapy may offer the greatest advantages, such as reirradiation for recurrent disease, post-operative pelvic irradiation, and extended field nodal treatment. This review also emphasizes current constraints that have slowed down wide clinical implementation, such as the lack of mature prospective data, cost, and accessibility. Finally, we emphasize future directions, including well-designed comparative trials, integration with systemic and immunotherapies, and adaptive treatment strategies. As the body of accumulated evidence evolves, the proton beam therapy potential for the treatment of gynecological malignancies has tremendously increased due to its role in safety and personalization of radiation treatment.
To Ablate or Not to Ablate: The Colorectal Liver Metastasis Question
Woodrum, David A.

Radiology | June 30, 2026 | Volume: 319 | Issue: 3 | Pages: No page available

10.1148/radiol.261067 | PMID 42377130 Get It

A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer
Heumann, Thatcher , Lu, Jiayun , Wang, Hao , Phelps, Mitch A. , Zhu, Qingfeng , Anders, Robert A. , Mitchell, Sarah , Leatherman, James M. , Abbott, Nicole , Kim, Kyeongmin , Imhof, Teresa , Xie, Zhiliang , Partey, Alexandra , Kunk, Paul R. , Iyer, Renuka , Fonkoua, Lionel Aurelien Kankeu , Kalyan, Aparna , Gbolahan, Olumide B., Javle, Milind , Davis, S. Lindsey , Spencer, Kristen , Azad, Nilofer S. , Heumann, Thatcher Ross , Phelps, Mitch , Anders, Robert , Leatherman, James , Li, Daneng , Kunk, Paul Raymond , Iyer, Renuka , Dayyani, Farshid , Fonkoua, Lionel Aurelien A Kankeu , Kalyan, Aparna , Gbolahan, Olumide B , Javle, Milind M , Davis, S Lindsey , Florou, Vaia , Spencer, Kristen , Sharon, Elad , Yarchoan, Mark , Lesinski, Gregory B , Azad, Nilofer , Wang, Hao , Mitchell, Sarah , Li, Daneng , Dayyani, Farshid , Sharon, Elad , Yarchoan, Mark

Clinical Cancer Research | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF12

10.1158/1078-0432.ccr-25-4893 | PMID 42377085 Get It

Abstract Purpose: The addition of MEK inhibition (MEKi) to programmed cell death ligand 1 (PD-L1) blockade improves progression-free survival (PFS) in patients with advanced biliary tract cancer. Although MEK inhibitors may increase tumor cell immunogenicity, they can impair T-cell priming/effector function, limiting combination efficacy. We hypothesized that the addition of a CD27 agonist could restore T-cell function and enhance antitumor immunity in this combination. Patients and Methods: We conducted a randomized, phase II trial evaluating atezolizumab (840 mg, intravenously, days 1 and 15) in combination with the CD27 costimulatory monoclonal antibody [CDX-1127/varlilumab (3 mg/kg, intravenously, days 1 and 15)], with/without the addition of an MEK inhibitor [cobimetinib (60 mg, orally, daily, days 1–21, off days 22–28)] in unresectable biliary tract cancer following at least one metastatic therapy. Overall response rate (ORR) and PFS were coprimary endpoints. Treatment-related changes in CD8+ tumor-infiltrating lymphocytes (TIL) were the primary correlative outcomes. Results: The trial was closed early following interim preplanned ORR analysis. At closure, 57 patients had been enrolled [n = 29 in the cobimetinib + atezolizumab + varlilumab (CAV) arm; n = 28 in the atezolizumab + varlilumab (AV) arm]. A majority (67%) had intrahepatic cholangiocarcinoma, and 32% were immunotherapy experienced. Both regimens were well tolerated without new safety signals. Objective responses were rare [0% (CAV); 3.8% (AV)]. The median PFS (mPFS) was 2.40 (CAV) and 1.84 (AV) months [hazard ratio (HR), 0.67; 95% confidence interval (CI), 0.38–1.18]. Among immunotherapy-experienced patients, the mPFS was 3.62 (CAV) and 1.84 (AV) months (HR, 0.54; 95% CI, 0.18–1.62). Treatment with CAV increased intratumoral CD8+ T-cell density compared with treatment with AV. Conclusions: The combinations of atezolizumab and varlilumab with/without cobimetinib were safe, but neither meaningfully improved outcomes in biliary tract cancer treated in the later lines. Correlative tissue studies validated preclinical work that MEKi increases CD8+ TILs.
Hip Arthroscopy Femoroplasty Resection Characteristics as They Relate to Postoperative Clinical Outcomes: A Retrospective Cohort Study
Uvodich, Mason E., Baker, Hayden P., Capitano, Alex V. , Raghuram, Akshay K. , Nawabi, Danyal H. , Coleman, Struan H. , Kelly, Bryan T., Buza, Stephanie S., Uvodich, Mason E. , Baker, Hayden P. , Capitano, Alex , Raghuram, Akshay K. , Ranawat, Anil S. , Kelly, Bryan T. , Buza, Stephanie Swensen

HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery | June 30, 2026 | Volume: 22 | Issue: 5 | Pages: 465-473

10.1177/15563316261459986 | PMID 42388999 Get It

Background: Adequate cam resection during hip arthroscopy for femoroacetabular impingement syndrome (FAIS) is necessary to restore femoral head-neck offset while avoiding under- or over-resection. The relationship between the extent of femoroplasty and postoperative patient-reported outcomes remains unclear. Purpose: We sought to answer the following questions: What is the association between the extent of cam femoroplasty resection and postoperative improvements? and is a 5% resection threshold associated with improved outcomes? Methods: We conducted a retrospective review of patients with adequate acetabular coverage who underwent primary hip arthroscopy with femoroplasty between January 2015 and December 2022 at our institution and had preoperative and 1- and/or 2-year postoperative modified Harris hip score (mHHS) and/or International Hip Outcome Tool (iHOT) scores. We included 400 patients (409 hips; ages 14–50 years). Outcomes included score changes and achievement of minimum clinically important difference (MCID) and substantial clinical benefit (SCB). Postoperative Dunn lateral radiographs quantified femoroplasty by resection depth percentage (resection depth/femoral head diameter), proximal resection angle, and postoperative α angle. Hips were classified as under-resection, neutral (0%–5%), or over-resection (>5%), and differences in outcomes were compared between resection groups. Multivariable regression analyses controlled for demographic, radiographic, and surgical variables. Results: Mean resection depth was 4.8%; mean proximal resection angle was 72.6°. No differences were observed in score improvements or MCID/SCB rates between groups with under-resection versus over-resection at 1 or 2 years. Greater resection depth was associated with larger 1-year mHHS and iHOT improvements and independently predicted 1-year iHOT MCID and SCB. Higher proximal resection angle predicted 2-year iHOT MCID. Conclusion: In this retrospective, single-institution cohort study, we found that in patients with FAIS, greater femoroplasty depth was associated with improved 1-year clinical outcomes. Level of Evidence: Level III, retrospective cohort study.
HER2 Alterations in Squamous Cell Lung Cancer: Biology, Therapeutic Landscape, and Emerging Precision Approaches
Elantably, Dina , Meerzaman, Isabella, Hou, Alicia Y. , Abdelhakeem, Ahmed, Lou, Yanyan, Elantably, Dina , Hou, Alicia Yunxin , Lou, Yanyan

Cancers | June 30, 2026 | Volume: 18 | Issue: 13 | Pages: 2121

10.3390/cancers18132121 | PMID 42449663 Get It

Squamous cell lung cancer (SqCLC) accounts for 20–30% of non-small cell lung cancer (NSCLC) and remains associated with a poorer prognosis compared with adenocarcinoma. Despite advances in treatment, 5-year overall survival for advanced (stage IV) disease remains below 10–15%. Unlike non-squamous NSCLC, SqCLC is characterized by a high tumor mutational burden and complex genomic landscape dominated by alterations in tumor suppressor genes and lineage survival pathways including TP53, CDKN2A, PIK3CA, FGFR1, SOX2, and the NFE2L2/KEAP1 oxidative stress pathway, as well as dysregulation of the NOTCH signaling pathway, but it harbors relatively few actionable oncogenic drivers, resulting in limited treatments for targeted therapy. HER2 alterations can occur by multiple mechanisms, including activating mutations, gene amplifications, and protein overexpression. They comprise a very small percentage of NSCLC, with HER2 mutations reported in approximately 1–3% and HER2 amplifications observed roughly in 2–4%. While HER2 alterations are well characterized in lung adenocarcinoma, the prevalence, genomic context, and clinical significance of HER2 alterations in SqCLC remain incompletely defined. Advances in next-generation sequencing have led to improved ability to detect HER2 alterations and facilitated the development of HER2 targeted therapies. Available treatments for advanced/metastatic SqCLC have been historically limited to platinum-doublet chemotherapy, with immune checkpoint inhibitors such as anti-PD-1/PD-L1 newly emerging in the past decade. Selective HER2 tyrosine kinase inhibitors and HER2 antibody/drug conjugates have shown improved efficacy in HER2-altered NSCLC as shown in DESTINY-LUNG02 and BEAMION LUNG-1 trials; however, most of the enrolled patients had non-squamous histology, with minimal or no SqCLC-specific efficacy data reported. Future progress in HER2-altered SqCLC will require inclusion of SqCLC in HER2 basket trials, incorporation of comprehensive molecular profiling and standardized HER2 testing in squamous histology. This review summarizes the current state of knowledge of HER2 biology in SqCLC and highlights areas for future directions for precision oncology in SqCLC.